Trial Profile
A Randomized, Double-Blind, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once Daily Oral Vonoprazan 20 mg or Vonoprazan 40 mg Compared to Esomeprazole 40 mg for the Treatment of Subjects With Symptomatic Gastro-Esophageal Reflux Disease Who have a Partial Response Following Treatment with a High Dose of Proton Pump Inhibitor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2023
Price :
$35
*
At a glance
- Drugs Vonoprazan (Primary) ; Esomeprazole
- Indications Gastro-oesophageal reflux
- Focus Proof of concept; Therapeutic Use
- Sponsors Takeda
- 01 Jan 2023 Primary endpoint has not been met (Percentage of Heartburn-Free 24-Hour Periods (Day and Night) During 4 Weeks of Treatment) , according to Results published in the Neurogastroenterology and Motility
- 01 Jan 2023 Results published in the Neurogastroenterology and Motility
- 15 Oct 2018 Status changed from recruiting to completed.